Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Fast Track Designation to Givastomig for Frontline HER2-Negative Metastatic Gastric Cancer
2
FDA Approves Capivasertib Plus Abiraterone and Prednisone for PTEN-Deficient Prostate Cancer
3
FDA Accepts BLA for Ozekibart in Unresectable or Metastatic Chondrosarcoma
4
Talquetamab Plus Daratumumab Improves PFS vs SOC in R/R Multiple Myeloma
5